A collection of stock notes from around the web.
August 11, 2009
$30 Price Target on Human Genome Sciences
that Leerink has set a new price target of $30 on Human Genome Sciences due to the likely hood of positive Phase II trial data for BLISS-76.
Human Genome Sciences
Post a Comment
Post Comments (Atom)